- project . 2019 - 2022Funder: EC Project Code: 821513Overall Budget: 2,353,120 EURFunder Contribution: 1,199,120 EUROpen Access mandate for Publications and Research DataPartners: Roche (Switzerland), NICE, TAKEDA DEVELOPMENT CENTRE EUROPE LTD, SYNAPSE, Eli Lilly and Company Limited, JANSSEN PHARMACEUTICA NV, AE, PARKINSON'S UK, TPIZ, SARD
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dov...
- project . 2019 - 2022Funder: EC Project Code: 806999Overall Budget: 7,644,400 EURFunder Contribution: 4,999,760 EUROpen Access mandate for PublicationsPartners: STICHTING VUMC, UOXF, SOFTWARE AG, Karolinska Institutet Innovations (Sweden), Eli Lilly and Company Limited, ALTOIDA SA ALTOIDA LTD, AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN, Fraunhofer, Novartis Pharma AG, KCL...
There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful c...
- project . 2018 - 2021Funder: EC Project Code: 807012Overall Budget: 3,100,690 EURFunder Contribution: 1,750,000 EUROpen Access mandate for Publications and Research DataPartners: UMC, IAPO, Eli Lilly and Company Limited, ASTRAZENECA AB, SARD, VT, GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD., UCB Pharma (Belgium), UNIVERSITAIR MEDISCH CENTRUM GRONINGEN, NICE...
The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practices from IMI GetReal and increase the quality of real-world evidence (RWE) generation in medicines development and regulatory/HTA pr...
- project . 2019 - 2022Funder: EC Project Code: 821362Overall Budget: 8,872,550 EURFunder Contribution: 4,599,650 EUROpen Access mandate for PublicationsPartners: Charité Universitätsmedizin Berlin, JANSSEN PHARMACEUTICA NV, BIONEER A/S, UCB Pharma (Belgium), Eli Lilly and Company Limited, ARTTIC INNOVATION GMBH, DH, H. LUNDBECK AS, Novo Nordisk, TAKEDA DEVELOPMENT CENTRE EUROPE LTD...
EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells...
- project . 2019 - 2024Funder: EC Project Code: 831514Overall Budget: 27,200,800 EURFunder Contribution: 15,000,000 EUROpen Access mandate for PublicationsPartners: WWU, Roche (Switzerland), VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY, FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE, STICHTING VUMC, UNIVERSITAIR MEDISCH CENTRUM GRONINGEN, TAKEDA DEVELOPMENT CENTRE EUROPE LTD, VUB, Imaginab Inc, TTOP...
Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a person...
Powered by OpenAIRE Research Graph